* Antex Biologics, of Gaithersburg, Md., began a safety andimmunogenicity trial of an oral vaccine and mucosal adjuvant forCampylobacter bacteria. A previous Phase I trial did not include theadjuvant.
* AntiCancer Inc., of San Diego, received a $750,000 Small BusinessInnovation Research grant to further develop DermaTek, a hair-growth technology using liposomes to deliver compounds or genes tothe hair follicle to protect hair from the effects of chemotherapy.
* Cell Therapeutics Inc., of Seattle, was awarded a Small BusinessTechnology Transfer grant titled, "The effect of phosphatidic acidinhibitors on experimental allergic encephalomyelitis." The grant willenable the study of molecular mechanisms and effects of novel anti-inflammatory agents developed by the company on autoimmunedemyelinating diseases of the central nervous system.
* Genta Inc., of San Diego, presented preclinical and interim clinicaldata showing biological activity of its lead antisense compound,G3139, against several tumor types. The product, which targets theproto-oncogene BCL2, is in a Phase I/IIa trial in non-Hodgkin'slymphoma.
* Genzyme Corp., of Cambridge, Mass., signed a definitiveagreement to purchase all outstanding units of Neozyme II Corp. for$45 per unit in cash, or about $109 million. Neozyme was formed in1992 to fund work for Genzyme related to cystic fibrosis. The deal isexpected to close later this year. (See BioWorld Today, Sept. 9,1996, p. 1.)
* Isis Pharmaceuticals Inc., of Carlsbad, Calif., presented updatedinformation from an ongoing open-label study of fomivirsen (ISIS2922) in cytomegalovirus retinitis showing the antisense compoundhas an acceptable safety profile characterized by low retinaldetachment rate, manageable local ocular complications and nosystemic side effects. The drug is in a pivotal study with resultsexpected by early 1997.
* Oncor Inc., of Gaithersburg, Md., created a strategic advisoryboard, headed by John Pappajohn, to help the board of directorsevaluate opportunities.
(c) 1997 American Health Consultants. All rights reserved.